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Abstract
Donation after circulatory death (DCD) is a potential avenue to narrow the gap between demand
for donor hearts and their limited supply. DCD was abandoned after 1970 where donation of
organs after brain death became the standard, however DCD has made a recent resurgence for
organ donation, predominantly for lung transplants which has shown much success. Heart
transplant donors primarily source from brain dead donors. Benefits of DCD for heart transplants
include an expanded donor pool to address the drastic shortage of supply and reduced onerous
financial burden. Drawbacks of heart DCD include substantial ischemia reperfusion injury (IRI)
and inflammation experienced by the donor heart. IRI changes the metabolic phenotype of the
myocardium, compromising its efficiency. Pharmacological interventions by manipulating
metabolic signaling pathways can shift the myocardium towards cardioprotective phenotypes to
maximize the integrity of the organ during the stressful transplantation process. Lastly, a process
of ischemic pre and post conditioning of the heart tissue to facilitate an incremental adjustment
to ischemic conditions as a therapeutic approach is desirable. We review the practicality of DCD
along with the financial and logistical constraints of implementing this technology, including the
optimization of signaling pathways and conditioning strategies to reduce IRI in heart transplant.
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Introduction
There is a huge shortage of donor organs on a global scale and the supply cannot hope to meet
the current demands. Heart transplants are particularly problematic since they have been and
remain the best avenue for clinical treatment of patients with end stage heart failure. To increase
the donor pool and increase the available supply of hearts, clinicians have looked to bringing
back donation after circulatory death (DCD) as a means of closing the gap between the supply
and the demand for donor hearts.
Generally, there are three types of organ donors. The first is the living donor where the donor is
alive and usually donating to family or a loved one. The second is a donor who has been
classified as brain dead. These donors have been declared dead based on neuro criteria, however
their heart beat is still intact. Organ donation is predominantly from brain dead donors. The last
major category is the donor who has experienced circulatory death. These patients have
experienced irreversible circulatory and respiratory arrest and are considered dead at that point.
Historically DCD took place between 1951 and 1967 and included kidney, liver and heart
transplants. In 1968, the Harvard Committee established brain death criteria and brain death
became the standard after its acceptance in 1970, which effectively put a damper on using DCD
donors for their organs. Recently there has been a move to increase the donor pool by
reintroducing the DCD to meet the overwhelming demand for donor organs.

Donation after brain death (DBD) has been the traditional source of solid organ transplants.
However, between 2001 and 2008, DBD transplants have gone from virtually a 100% of
donations, down to 55%, not because of fewer DBD donors per se, but because of the
tremendous increase in DCD donors. This trend has not manifested for heart transplants and
during this period, essentially all the heart transplants came from DBD.1
A pilot study at the University of Alberta demonstrated success using DCD for lung transplants.
They reported significantly reduced cold ischemic times due to usage of ex vivo lung perfusion
and reduced primary graft dysfunction 72 hours post-transplant. These results had similar
mechanical ventilation times and length of stay in the hospital compared to traditional lung
transplant methods.2 These findings suggest that similar results can be attained using heart
transplant models.
From an economic and humanitarian standpoint, patients waiting on transplant lists are often put
on LVADs to prolong their ability to wait. This is traumatic and stressful for the patient, not to
mention costly for the patient and the system overall, both of which could be eased with an
increase in donor pool which is possible by harvesting DCD hearts.1
DCD heart transplantation has been shown to be successful in both animal models (sheep and
primate) and humans (adult case in 1967 and pediatric cases in 2007).3 – 5 The human studies
required that warm ischemic conditions for the donor heart be limited to 30 minutes, which
becomes an issue during explantation and implantation of the organ as it is cut off from
circulation/perfusion. Ex vivo perfusion and close monitoring of the organ tissue in conjunction
with a therapeutic perfusate can help to optimize these results.
This review will explore some of the benefits and drawbacks to using DCD for heart transplants
and will focus largely on the cellular environment during ischemic-reperfusion injury, one of the
main points of contention with using DCD.
Benefits of DCD Usage
Brain death accounts for a small proportion of mortality in the US, whereas circulatory and
cardiovascular death account for a significantly greater fraction of deaths. As such, the donor
pool is much larger with DCD and can vastly ameliorate the shortage of donor organs by as
much as 40%.6 – 8 In addition, DCD hearts can be transplanted via traditional cold static storage
methods or using ex vivo perfusion methods. In the latter case, the viability of the organ ex vivo
is significantly longer, close to 10.5 hours as documented by Australia, while cold static storage
averages around 4 – 6 hours of viability.5 This increase in time would increase the radius
between donor and recipient for a transplant and would even make trans-Atlantic donations
between countries possible, on top of having a larger donor pool from using DCD. These
benefits alone warrant exploration of DCD in heart transplants as it has been adopted to for other
organ transplants.
Drawbacks
There are some hurtles, both ethical and procedural, that need to be overcome before heart DCD
transplants become commonplace. Ethical dilemmas include the amount of time that must be

observed between circulatory death and donor organ harvest and pre-mortem pharmacological
interventions to limit damage to heart. Procedural issues relate to the onset of warm ischemia in a
DCD heart, DCD physiologic effects, extubation comorbidities and ischemia-reperfusion injury.
One of the drawbacks associated with using hearts obtained from donors after circulatory death
is that donors who have experienced brain death often exhibit a Cushing response. This is
sympathetic system response that results in a massive cytokine release after brain death that has
been shown to alter the phenotype of the donor organ. Animal studies in baboons have shown
that not only can the cytokine cascade potentially damage the cardiac tissue, but the surface
antigens have been altered to promote inflammation. This combination of damaged tissue and
pro-inflammatory phenotypes has been observed to increase the risk of graft rejection and
reduced positive long-term outcomes for kidneys.9, 10
Extubation of a DCD heart donor resulted in hypoxic pulmonary vasoconstriction. This was
observed with right ventricular distension and concurrent reduced cardiac output. Both events
were followed by a 120-fold increase in epinephrine levels which further exacerbated the right
ventricular distension. The large catecholamine release following extubation can compromise the
integrity of the cardiac tissue and close monitoring and management of these physiologic
changes is necessary before transplanting a DCD heart.11
Ischemia and Reperfusion
One of the issues with all forms of heart transplant is ischemic-reperfusion injury. Ischemic
conditions are experienced during harvest and implantation of the donor organ. As such it is
important to identify the cellular factors at play during ischemic conditions and identify how to
intervene to limit the damage. Extended criteria hearts are more fragile by definition, as such it is
important to limit the insult that they experience during the transplant procedure to ensure
maximal functionality after transplant. Characterizing the ischemia and reperfusion injury to
heart tissue in the context of transplants will be the focus of the remainder of this paper.
Ischemia reperfusion injury refers to the damage that takes place in the tissue due to a lack of
oxygen under ischemic conditions, followed by additional tissue damage that takes place as the
oxygen is restored during reperfusion. Restoration of flow through the tissue brings with it fresh
nutrients and flushes out toxic build up, but this process jump starts the cellular metabolism of
the tissue and can result in many side effects that culminate in tissue damage.

AMPK Pathway and Metabolism
Approximately 60 – 80% of myocardial ATP production comes from fatty acid oxidation and the
remaining 20 – 40% from glycolysis and ketone body oxidation. Ischemia and reperfusion cause
fluctuations and change the metabolic phenotype of the heart and this in turn effects the
myocardial function.12 Increasing evidence has shown that enhancing glucose metabolism and
inhibiting fatty acid oxidation in the ischemic heart has a beneficial effect for maintaining
cardiac efficiency. Hence increasing glucose uptake and metabolism in ischemic hearts can
provide protective phenotypes relative to fatty acid oxidation.12
Flux through fatty acid β-oxidation is dependent on several factors including the presence and
concentration of free fatty acids in the plasma. During surgical stress or ischemic stress, as is the
case during harvest and implantation of a donor organ, there is a surge of catecholamine release
and these hormones increase the plasma concentration of free fatty acids by increasing the rates
of lipolysis. β-oxidation is regulated by malonyl CoA which is formed intracellularly via the
conversion of acetyl-CoA by the enzyme acetyl-CoA carboxylase (ACC). ACC is activated via
the 5’AMP activated protein kinase (AMPK) pathway, a pathway that regulates many metabolic
processes.13
In addition to ACC, Notch1 and liver kinase beta1 (LKB1) also come together to modulate the
AMPK activity, specifically reducing glucose oxidation and fatty acid oxidation during ischemia
reperfusion. Slowing down these biochemical processes naturally reduce the production of
radical oxygen species and limits the damage of reperfusion. As such, activation of the AMPK
signaling pathway via Notch1’s interaction with LKB1 has been shown to induce
cardioprotective properties against ischemia reperfusion injury.13
The AMPK pathway is also triggered when the AMP/ATP ratio is elevated. Activation of AMPK
facilitates conservation of cellular energy stores, increases ATP formation and decreases ATP
usage during ischemic conditions. AMPK pathway and STAT3 pathways, when activated by
leptin signaling, which also limits structural and functional damage to cardiomyocytes, reduces
glycolysis, cardiac hypertrophy, apoptosis, and inflammation in post myocardial infarction
hearts.14, 15 Interestingly, leptin is associated with lipolysis and increased free fatty acid
formation which is detrimental to metabolic processes in ischemic conditions, suggesting that
there are complicated interactions between signaling molecules and their downstream effects.
Nonetheless, these protective effects are lost in AMPK knockout mice and suggest that these are
physiologic protective functions. To facilitate this protection in ex vivo perfusion during
ischemic reperfusion, it might be worthwhile to induce NOTCH1 and LKB1 signaling to induce
the AMPK pathway, concurrent with inhibition of ACC to limit β-oxidation, in the heart to jump
start the protective facilities and limit peripheral side effects.
Since most of myocardial energy comes from fatty acid oxidation which is dependent on the
presence of oxygen (for the electron transport chain in the production of ATP), ischemic
conditions halt the bulk energy production. In terms of energy, a single molecule of palmitate
(fatty acid) produces 105 molecules of ATP via β-oxidation, in contrast to the 31 ATP molecules
produced by glycolysis of a single glucose. β-oxidation requires oxygen however, whereas
glycolysis does not and as such the phosphorous/oxygen ratio, a measure of ATP produced per

atom of oxygen reduced by the electron transport chain, and a proxy for cardiac efficiency,
favors glycolysis by as much as 25 – 40%.16
Furthermore, cardiomyocytes express uncoupling proteins, UCP3 specifically among a few other
isoforms, which essentially break the flow of electrons in the electron transport chain. UCP3 is
activated in ischemic conditions when there are higher levels of free fatty acids and exports their
intermediate break down products from the mitochondria, preventing accumulation of charged
species within the matrix. This process requires the action of acyl-CoA synthase which uses 4
equivalents of ATP by converting 2 ATP to AMP and PPi. Since ADP isn’t being generated, this
process further hinders regeneration of ATP since glycolysis requires ADP as a substrate.17
Glycolysis also produces pyruvate, a charged product, which needs to be transported into the
mitochondria to enter the tricarboxylic acid cycle for further oxidation. The transport of pyruvate
is coupled with protons, however when this process is uncoupled, can result in intracellular
acidosis. This is particularly problematic in ischemic conditions as these toxic metabolic wastes
can’t be flushed out, compromising cardiac efficiency and functionality.12
As ATP generation becomes more difficult, cardiac efficiency plummets. What little energy is
produced to maintain cellular integrity via anaerobic metabolism, i.e. glycolysis without pyruvate
oxidation, results in lactic acidosis. As ATP depletion manifests, ion homeostasis is also
compromised as sodium and potassium concentration gradients can’t be sustained without the
action of ATPases, resulting in intracellular sodium overload and potassium deficiency and
inability of the cell to reuptake cytosolic Ca2+ into the sarcoplasmic reticulum.12
After ischemic conditions end, fatty acid oxidation resumes to normal levels, however glycolysis
and cardiac efficiency, and as a result the mechanical function of the heart don’t return to
normal. Reperfusion attempts to restore the cytosolic levels of protons across the sarcolemma,
but this effects the Na+/H+ exchanger and increases the already elevated Na+ concentration as it
returns cytosolic proton concentration to normal.12 The Na+ levels are attempted to be balanced
by activating the Na+/Ca2+ exchanger which pumps out 3 Na+ for every Ca2+ pumped in resulting
in intracellular calcium overload. Calcium homeostasis is integral for maintaining the contractile
functionality of the myocardium as the actin-myosin filament cannot properly function.12
As mentioned earlier, ischemia induces significant catecholamine release resulting in increased
lipolysis and free fatty acids. An adverse reaction that stems from this is the development of
insulin resistance systemically as this prevents GLUT transporters from making it to the
myocardial surface and limits glucose transport into the cell. As such reverting to anaerobic
metabolism becomes difficult even under anaerobic conditions.18, 19 Activated protein C (APC)
increases AMPK signaling and results in increased GLUT4 transporter translocation into the
plasma membrane of cardiomyocytes. This facilitates preferential glycolytic metabolism over
fatty acid oxidation and can potentially counterbalance the insulin resistive effects of
catecholamine release.20
Since the cardiac efficiency and potassium/oxygen ratio favors glycolysis, it seems that
exploring pharmacological therapies that target changing in metabolic flux to favor glycolysis
can favor cardiac mechanical efficiency. Using inhibitors of beta-oxidation such as malonyl-CoA
decarboxylase inhibitors, beta blockers to inhibit catecholamine release which in turn would
reduce heart rate, lipolysis and increase glucose oxidation.21 Drugs such as ranolazine,

trimetazidine and etomoxir essentially shuttle metabolism towards glucose oxidation by shutting
down fatty acid oxidation at different stages. Increasing glucose oxidation under ischemic
conditions can be an effective way of improving ATP generation efficiency without sacrificing
cardiac function.12
Role of Calcium
Increases in intracellular Ca2+ concentration combined with the presence of reactive oxygen
species (ROS) species as is the case during ischemic conditions, triggers the opening of a
mitochondrial conductance channel referred to as the mitochondrial permeability transition
(MPT). This channel results in a loss of ATP, compromised mitochondrial function, induction of
mitochondrial swelling resulting in loss of mitochondria membrane integrity and triggering
release of cytochrome c and inducing apoptosis.22 This is in addition to the myocardial
autophagy that takes place due to high levels of intracellular Ca2+ that resulted from ischemic
conditions.23 Intracellular Ca2+ stores rise by reverse reaction of the Na+-Ca2+ exchanger due to
the build-up of intracellular Na+ from the balancing out effects of proton gradients mentioned
earlier. Inhibition of either the Na+-H+ exchanger or the Na+-Ca2+ exchanger have both shown
cardioprotective properties against reperfusion injury. The build-up of protons results in an
acidic intracellular pH, and under ischemic conditions the extracellular fluid also becomes acidic.
Reperfusion restores extracellular pH rapidly as the contents are readily flushed out. The
intracellular pH is restored through the actions of the exchangers, largely through the Na+-H+
exchanger. The intracellular Na+ concentration is then balanced out by exchanging it witch
extracellular Ca2+.22 Ca2+ is necessary to maintain and induce muscle contractions and when the
intracellular concentrations rise in myocytes, it can result in arrhythmias or hyper-contractions
which can result in cell death or other irreversible cellular injury during ischemia-reperfusion.
Preventing the unregulated influx of Ca2+ has shown to be effective in protecting against this.
Inhibition of Na+-Ca2+ exchanger by agents such as SEA0400 have even shown to be able to
maintain mitochondrial function and cellular ATP content under ischemic conditions.24
ROS
ROS species have been shown in many studies to be generated during reperfusion after
ischemia.22 The current hypothesis is that ROS species increase during ischemic and reperfusion
states is due to damage to the electron transport chain which results in poor electron transfers and
incomplete oxidation-reduction reactions resulting in the production of superoxide radicals. ROS
species are also secreted by neutrophils and monocytes that have infiltrated the tissue during
early reperfusion as a part of the inflammatory response.25 The ROS species can damage the cell
themselves or induce the expression of mitochondrial transition pores in the inner membrane.
Several animal models have been tested with the addition of antioxidants such as superoxide
dismutase and catalase as well as some protective vitamins such as vitamin E and vitamin C, to
limit the effect of the free radicals, as well as being treated with chemokine inhibitors such as
Evasin-3.25, 26 Chemokine inhibition was shown to have ameliorative effects, while the results for
the antioxidant treatments were split with some studies reporting reduction in infarct size,27, 28
while others reporting there were no significant reductions in infarct size.29, 30 The conflicting
results could be indicative that the antioxidant agents were not able to scavenge the radicals
before they had already compromised the integrity of the myocyte, and that administration of

these clinical therapies is time sensitive or must be precautionary as opposed to reactionary in
order to demonstrate cardiomyocyte protection, however these findings are still unclear.
Preconditioning
Ischemic preconditioning (IPC), which is treatment of the heart with short cycles of ischemic and
reperfusion periods of 5 minutes or so, was first introduced approximately 20 years ago as a
means of reducing ischemic damage to tissues under prolonged periods of ischemia.31. Hearts
that are preconditioned, experience reduced instances of anaerobic metabolism and reduced
ischemic lactic acidosis. The cellular cascade that results in the cardioprotective effects of
preconditioning is included below.22 The first have of Figure 1 is a cascade showing the effects
of IPC while the second half of the figure is the cascade showing the effects of ischemic post
conditioning. Both pathways converge to inhibit mitochondrial permeability transition pores
(MPT pores) which were mentioned earlier. Inhibition of MPT seems to be an effective method
of inducing cardioprotection and has been shown using drugs such as cyclosporin.32

Figure 1. Ischemic pre and post conditioning signaling pathway. Taken from Mechanisms
Underlying Acute Protection from Cardiac Ischemia-Reperfusion Injury.22
It is suggested that the short cycles of ischemia and reperfusion slow down the rate of ATP

hydrolysis since there is less ATP production taking place (due to the intermittent anaerobic
glycolysis).33 The attenuation of the rate of ATP hydrolysis likely conditions the cell and persists
into the global prolonged ischemic conditions for the tissue, likely aiding in preventing the
depletion of energy stores. A second method by which IPC can be protective is by preventing
ATP breakdown by the mitochondrial ATPase which functions in reverse to the ATP synthase
molecule from the electron transport chain.34 When the mitochondrial membrane potential is
thrown off balance due to pH imbalances under ischemic conditions, the ATPase molecule can
break down ATP molecules (which are charged molecules) to restore the membrane potential.
There is conflicting evidence for protecting and stimulating ATP levels in relation to ATPase
activity in the mitochondria after preconditioning.35, 36
IPC results in phosphorylation of the PI3K/Akt pathway which propagates a pro-survival signal
during times of ischemic reperfusion. The activation of this pathway releases hydrophobic
mediators into the coronary circulation and has been characterized as reducing infarct size by
55% compared to controls. Inhibition of this pathway, eliminated any protective properties that
were observed using the IPC treatment. Using the effluent from a heart that has undergone IPC
in the coronary circulation of another heart has also protected against infarct size, namely
through the PKC pathway which is just downstream of the PI3K pathway.37 – 39 IPC has also
been characterized to induce other RISK survival pathways including the ERK pathway. These
pathways branch at several levels but converge and induce cardioprotection by ultimately
inhibiting MPT. Inhibition appears to be time sensitive and the most effective and pronounced
reduction in infarct sizes appears to be at the beginning of reperfusion.40 Furthermore, metabolic
analyses of IPC have shown that SIRT1, a lysine deacetylase, is required in IPC treatments to
target various metabolic regulatory systems. IPC induced the following changes in the
myocardium: increased glycolysis, glycogen and amino acid synthesis, reduction in glutathione
levels, and inhibited fatty acid oxidation. These pathways were not affected as such when SIRT1
was inhibited and the protective capacity of IPC treatments were eliminated with SIRT1
inhibition.41
Hypothermia and Post Conditioning
Mild hypothermic conditions (32 – 35 degrees Celsius) at the onset of reperfusion for a short
period of time (approx. 10 minutes) has shown improvements in post ischemic heart
functioning.42 This intervention improved left ventricular work capacity, as well as improved the
pressure, heart rate, contraction rate and cardiac output compared to hearts that did not receive
the hypothermic intervention. These same parameters were also improved when they treated the
DCD hearts with mechanical post conditioning, i.e. 30 second cycles of ischemia and 30 seconds
of reperfusion, twice, directly at the time of initial reperfusion. They also measured reduced
levels of necrosis and cytochrome c release and higher levels of oxygen consumption, suggesting
improvements in post ischemic metabolism when treated with hypothermia. The protective
capacity of mild hypothermic conditions against infarctions was completely abrogated when
extracellular signal regulated kinase (ERK) inhibitors were administered. This suggests that the
protective capacity of the mild hypothermic treatments acts through the ERK signaling pathway.
Inhibition of ERK pathway did not change the levels of ATP preservation, although ATP
hydrolysis and metabolism are slowed because of this intervention.43

Mechanical postconditioning intervention also improved hemodynamics in hearts that were
exposed to high levels of free fatty acids, but reperfused with only glucose, favoring glycolysis
over fatty acid oxidation. This method of post conditioning works through shutting off
mitochondrial permeability transition pores.44, 45
Lastly, this group reported improvements in hemodynamic functions after inducing a brief period
of hypoxic reperfusion when compared with oxygenated reperfusion strategies. Specifically, they
saw improvements in left ventricular work, increased pressure, contraction and relaxation rate as
well as coronary flow. If the heart is perfused with glucose under hypoxic conditions, then the
ability to produce reactive oxygen species is drastically reduced and protective of the myocardial
tissue.
Conclusion
There have been clinical trials that have failed with the implementation of different drugs and
protocols and it’s important that further exploration into cardioprotective measures be taken to
reduce ischemia-reperfusion injury. Both the timing of administration and different drug
cocktails should be considered, i.e. MPT and ion exchange inhibitors and antioxidant treatments
early on reperfusion. DCD presents a way of reducing the burden of limited organs available for
donation and has been re-introduced into many transplant procedures. Heart transplants have not
however, and one of the fears is the deleterious effects of ischemic-reperfusion injury.
Nonetheless, by understanding the mechanisms of reperfusion injury and targeting them to
maximize heart transplant viability, DCD will become a more feasible option, both using cold
static storage methods as well as using ex vivo perfusion methodologies.
The UK and Australia have reintroduced DCD into their healthcare systems. St. Vincent’s
Hospital heart transplantation in Australia have also reported success using DCD heart
transplantation protocols and OCS in 2014. Currently the PROCEED II trials for heart
transplants with OCS are taking place, which is an FDA approved international trial. As of 2014,
128 patients have received an OCS ex vivo heart perfused transplant. Results of the trial were
released online in 2015 and both the primary effectiveness and safety endpoints (30-day patient
survival and serious adverse effects/rejection/ICU time) goals were met.46, 47 Success in these
trials and proper manipulation of cellular processes can optimize hear transplantation and limit
adverse outcomes.
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